Pivmecillinam
General Information
A penicillin antibiotic. Do NOT use if patient is allergic to penicillin.
Restricted formulary antimicrobial: For details see OUH netFormulary
AWaRe antibiotic classification: 'Access'. Use as per guidelines.
Standard dose
400mg po STAT then 8 hours later 200mg tds
Obesity
No dose adjustment required
Renal and hepatic impairment
Renal impairment
Dose adjustment is not necessary in impaired renal function.
If using for extended periods of time: Accumulation may occur in patients with severe renal impairment. Discuss with Micro/ID about the need to use a lower dose.
Hepatic impairment
Dose adjustment not necessary
Notable interactions
Methotrexate: Pivmecillinam can reduce excretion of methotrexate (increased risk of toxicity).
Valproic acid, valproate or other medication liberating pivalic acid: Avoid concurrent use due to increased risk of carnitine depletion.
Vitamin K antagonists: Appropriate monitoring should be undertaken. It would be prudent to monitor coagulation status within 3 days of starting or stopping a penicillin.
This is not a complete list. Please see the BNF, Summary of Product Characteristics or speak to a pharmacist.
Pregnancy and breastfeeding
Pregnancy
Discuss with pharmacy
Breastfeeding
Safe. Mecillinam is excreted in human milk, but at therapeutic doses of Pivmecillinam no effects on the breast-fed newborns/infants are anticipated. Pivmecillinam can be used during breast-feeding.
Additional information
Pivmecillinam contra-indications include patients with:
- any condition resulting in impaired transit through the oesophagus (e.g. gastro-intestinal obstruction or oesophageal strictures)
- genetic metabolism anomalies known to be leading to severe carnitine deficiency, such as carnitine transporter defect, methylmalonic aciduria or propionic acidaemia.
This is not a complete list. Please see the BNF, SPC or speak to a pharmacist.
Pivmecillinam should be used with caution in patients with porphyria since pivmecillinam has been associated with acute attacks of porphyria.
The intake of pivmecillinam shortly before delivery may cause a false positive test for isovaleric acidemia in the newborn as part of neonatal screening.
References
- Aurobindo Pharma - Milpharm Ltd. Pivmecillinam 200mg film-coated tablets summary of product characteristics: Electronic Medicines Compendium [Internet]. Last revision of the text: 26/10/2023. Accessed 14/12/23 from https://www.medicines.org.uk/emc/product/4982/smpc
- Karo Pharma AB. Selexid Tablets summary of product characteristics: Electronic Medicines Compendium [Internet]. Last revision of the text: 07/03/2023. Accessed 14/12/23 from https://www.medicines.org.uk/emc/product/3799/smp
- Joint Formulary Committee. British National Formulary (BNF). 27 September 2023 [Internet]. .Accessed 14/12/23 fromhttps://www.medicinescomplete.com
- Meng L, Mui E, Ha DR, Stave C, Deresinski SC, Holubar M. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update. Pharmacotherapy. 2023; 43(3):226-46
- The Renal Drug Database. Pivmecillinam Hydrochloride [Internet]. Revision date 22/5/23. Accessed 14/12/23 at: https://renaldrugdatabase.com/monographs/pivmecillinam-hydrochloride
- UK Teratology Information Service. Use of penicillins in pregnancy [Internet]. January 2019 [cited 2023 Oct 12]. Available from: https://uktis.org/monographs/use-of-penicillins-in-pregnancy/
- The Breastfeeding Network, Antibiotics and Breastfeeding [Internet]. October 2022 [cited 2023 Nov 20]. Available from: https://www.breastfeedingnetwork.org.uk/factsheet/antibiotics/
- Specialist Pharmacy Service. Pivmecillinam – Lactation Safety Information [Internet]. Revision date 21 September 2020 [cited Oct 12]. Available from: https://www.sps.nhs.uk/medicines/pivmecillinam/